Medicaid, Peripheral Arterial Disease and Technology

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Medicaid

Peripheral Arterial Disease

Technology

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 1 To date, interventional treatment of coronary artery disease with drug-eluting stents has been able to establish flow angiographically. of the U.S.

Coronary Artery Disease

Coronary Artery Disease Technology Stents Stent

R3 Vascular Receives WGC IRB Approval for its ELITE-BTK Pivotal Trial of its Next Generation Bioresorbable Scaffold

DAIC

JANUARY 13, 2025

a medical device company dedicated totreating peripheral arterial disease (PAD), recently announceit received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDEDrug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD).

Peripheral Arterial Disease

Peripheral Arterial Disease CMS Medicare Medicaid

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Cardiovascular Update

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

R3 Vascular Receives WGC IRB Approval for its ELITE-BTK Pivotal Trial of its Next Generation Bioresorbable Scaffold

Webinars

Stay Connected